Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GnRH antagonist monotherapy vs CAB with GnRH agonist plus bicalutamide in metastatic prostate cancer (KYUCOG-1401)
jRCTs071180035Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Randomised trial of degarelix, leuprolide, goserelin and bicalutamide in prostate cancer (PCa) (2 arms), sponsored by Astellas Pharma. Primary endpoint: PSA progression-free survival. Started Sep 2014; status: completed.
02
Drugs
degarelixleuprolidegoserelinbicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs071180035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180035.